MLex Comment: UK's Gaviscon damage claim puts spotlight on pharma companies' generic-delaying tactics
A damages claim by the UK health authorities against drug manufacturer Reckitt Benckiser reveals new details of the abusive strategy the company employed to delay generic competition to its blockbuster heartburn...To view the full article, register now.
Already a subscriber? Click here to view full article